What GLP-1 Actually Is and Why Drugs Like Ozempic Work

Listen to this article. Choose between:

You sit down with a sandwich and a bowl of soup, hungry enough that the first few mouthfuls are particularly welcome. As the meal continues, the experience changes. You may eat more slowly, leave a little on the plate, or find that the prospect of another sandwich has lost its appeal. Later, you get up and carry on with your afternoon, giving little thought to what happens to the food once you have swallowed it. From the outside, lunch seems straightforward: you were hungry, you ate, and now you are less hungry. Underneath that familiar experience, however, several processes are unfolding together. Food is moving through the digestive tract, nutrients are becoming available, and signals are influencing both how those nutrients are handled and whether you continue eating. The sensations you notice are only part of a much larger response.

One of the hormones involved in that response is glucagon-like peptide-1, usually shortened to GLP-1. Released from cells in the intestine after food arrives, it helps connect events in the digestive tract with responses elsewhere, including the regulation of blood glucose, the movement of food out of the stomach, and signaling involved in eating. GLP-1 is only one participant in that larger network, but its connections with the pancreas and nervous system help explain why it has become so important in medicine. Semaglutide, the drug sold under the Ozempic name, acts through the same receptor, yet remains available far longer than the natural hormone. That difference in duration changes the pattern of signaling enough that semaglutide cannot be understood simply as a meal response stretched across several days. The distinction becomes clearer once we see what GLP-1 is doing during an ordinary meal.

GLP-1 belongs to a group of hormones produced in the digestive tract. A hormone is a chemical messengerreleased by certain cells that influences the activity of others; GLP-1 is also a peptide, meaning it is builtfrom a short chain of amino acids. Those definitions can sound remote from the experience of eating lunch,but they point to an important feature of digestion. Breaking food down makes nutrients available forabsorption, while hormonal signaling helps coordinate what happens as those nutrients arrive. The intestineis therefore more than a surface through which nutrients enter the body. Cells within its lining also respondto what has been eaten and send signals that influence processes elsewhere. GLP-1 is one of thosesignals, connecting the presence of food in the digestive tract with changes in how the meal is handled.

The intestinal cells that produce GLP-1 are called L cells, and they are scattered through the intestinal lining rather than gathered in a separate gland. Nutrients from a meal stimulate these cells to release GLP-1, with carbohydrates, fats, and proteins all contributing to the response. GLP-1 is therefore not simply a signal that someone has eaten sugar, nor is its release confined to a single burst at the beginning of a meal. Secretion can continue as nutrients move through the digestive tract, making the pattern of exposure as relevant as the presence of the hormone itself. At any particular moment, the amount of active GLP-1 reflects both how much is being released and how quickly it is being removed. That balance between release and disappearance becomes especially important when the brief natural signal is compared with a drug designed to remain available much longer.

For GLP-1 to influence a cell, the cell needs a way to respond to it. That is the role of the GLP-1 receptor, a protein on the cell surface to which the hormone can bind. The familiar lock-and-key analogy is useful up to a point: it explains why a hormone can pass some cells without affecting them while changing the activity of others. But binding to the receptor is only the beginning. What follows depends on the kind of cell receiving the signal and the conditions at the time, which is why activation of the same receptor can contribute to different effects in the pancreas, digestive system, and nervous system. GLP-1 therefore makes more sense as one signal moving through an interconnected network than as a molecule with one fixed job. Its influence on the pancreas after a meal provides the clearest place to see that principle at work.

After a meal containing carbohydrate, digestion makes glucose available for absorption into the bloodstream, but the resulting blood glucose level depends on more than how much carbohydrate has just been eaten. It also reflects how quickly tissues take glucose up, how much is stored, and how much the liver releases. Two pancreatic hormones are central to that regulation. Insulin supports the use and storage of glucose, while glucagon helps maintain its availability from the liver, particularly between meals when nutrients are no longer arriving from the intestine. After eating, the changing balance between these hormones helps determine how incoming glucose is handled. GLP-1 contributes to that regulation by influencing the cells involved in their release, connecting the arrival of nutrients in the intestine with the pancreatic response that follows.

Insulin is released by pancreatic cells called beta cells. These cells respond to glucose, increasing insulin secretion as glucose rises. GLP-1 can amplify that response. The crucial qualification is that its insulin-stimulating effect is glucose-dependent: it is stronger when glucose is elevated and diminishes as glucose falls. Rather than supplying insulin itself, GLP-1 changes how the beta cells respond to the glucose available. This distinction matters when reading that a GLP-1-based drug “increases insulin.” That phrase can suggest a continuous increase regardless of circumstances, when the more useful idea is an enhanced response to a particular condition. A stronger response during rising glucose does not necessarily mean that more insulin will circulate across an entire day. Nor does glucose dependence mean that low blood glucose is impossible in every treatment setting. It describes an important feature of this signaling pathway, not an absolute guarantee about everything that can affect blood glucose.

Glucagon is released by a different group of pancreatic cells, called alpha cells. By promoting glucose release from the liver, it helps maintain glucose availability when the body needs it. During the response to a meal, however, glucose arriving from the intestine changes the balance required. GLP-1 can suppress glucagon secretion, reducing this additional contribution from the liver while also supporting glucose-dependent insulin release. The effect is regulation, rather than a complete shutdown of glucagon or the liver’s glucose supply. The biology behind it is also more complicated than GLP-1 simply attaching to an alpha cell and turning its activity down. Communication among cells within the pancreas contributes to the response, and direct action on alpha cells is not a settled, complete explanation. For the reader, the essential connection is that GLP-1 can influence both sides of glucose regulation: the response that helps use and store glucose, and the signal that promotes its release from the liver.

A small human study helps make this distinction more concrete. In a 12-week randomized trial involving 75 adults with type 2 diabetes, semaglutide improved the insulin response to an experimental glucose challenge compared with placebo. During a separate 24-hour meal assessment, however, glucose and glucagon levels were lower without a statistically significant difference in the total amount of insulin circulating over that period. The useful point is not that semaglutide simply produced more insulin, but that the response changed in relation to the conditions in which it was needed. The study does not establish permanent repair of insulin-producing cells, and findings in people with type 2 diabetes should not be generalized beyond that population. What it does illustrate is a broader principle of regulation: timing and responsiveness can matter as much as total output. The pancreas is only one part of that regulation, because the rate at which nutrients leave the stomach also shapes what the system has to manage.

The stomach does not pass everything you eat straight into the small intestine. It holds and processes the meal, gradually releasing its contents onward. This movement is called gastric emptying, and its pace influences how quickly nutrients become available for absorption. GLP-1 can slow that movement. Alongside its effects on pancreatic hormones, it can therefore influence the rate at which glucose from a meal reaches the bloodstream. These are connected parts of the same problem: the body has to handle both the arrival of nutrients and what happens to them afterward. But gastric emptying also helps explain why the experience of eating cannot be separated neatly from digestion. What is happening in the digestive tract contributes to signals involved in fullness and eating behavior. Slower emptying can be part of that picture, although it does not follow that every change in hunger, meal size, or body weight can be explained by food remaining in the stomach longer.

Everyday language tends to gather several experiences under the word “appetite,” although the biology becomes clearer when they are kept distinct. Appetite describes the desire to eat, satiation the process through which a meal becomes less appealing and comes to an end, and satiety the period afterward when hunger remains suppressed. At lunch, those distinctions correspond roughly to wanting the sandwich before you begin, becoming satisfied enough to stop eating, and then remaining comfortable without more food for part of the afternoon. The experiences overlap, but they are not interchangeable, either with one another or with observed behavior. A rating of hunger tells us something different from the amount someone actually eats, and neither reveals on its own which hormone or nerve pathway produced the result. GLP-1 participates in systems relevant to all of these experiences, but always alongside other signals involved in the regulation of eating.

Communication between the gut and brain travels through both chemical signals and nerves. Hormones released from the intestine interact with receptors, while sensory pathways, including those involving the vagus nerve, carry information from the digestive system toward the brainstem. What emerges is not a single message announcing that the stomach is “full,” but an integration of signals about the meal and the body’s current state with other influences on eating. GLP-1 adds another layer to this arrangement because certain nerve cells in the brainstem produce it independently of the intestine. Intestinal GLP-1 and brain-produced GLP-1 therefore belong to related but distinct signaling systems rather than one continuous stream running from a meal into the brain. That distinction matters because the effect of GLP-1 depends not only on the molecule itself, but on where it is produced, which receptors are accessible, and the conditions under which those receptors are activated.

The distinction between natural physiology and drug action becomes particularly important here. Experiments show that activating GLP-1 receptors can influence eating, and research has identified brain pathways involved in those effects, but much of the detailed work tracing particular nerve cells and responses comes from rodents. That evidence cannot provide a complete map of what happens to appetite in a person taking semaglutide, just as the drug’s ability to reduce food intake does not establish that naturally released intestinal GLP-1 controls ordinary human appetite to the same degree. Its contribution to everyday eating remains less straightforward than its established role in glucose-dependent insulin secretion. The more defensible picture is a coordinated response involving the digestive tract, pancreas, brain, and multiple signals, with GLP-1 influencing several points within that network. What distinguishes semaglutide begins with another property of the natural signal: each released molecule remains active only briefly.

Natural GLP-1 does not remain active for very long. Soon after it is released, an enzyme, a protein that carries out a chemical reaction, begins breaking it down. The kidneys also help remove it from the blood. Within roughly one to two minutes, the amount of active hormone would fall by about half if no more were being added. That can seem surprisingly brief for a hormone involved in the response to a meal, but the intestine can keep releasing more as food moves through it. Think of the distinction between a short message and a conversation that continues because new messages keep arriving. Each release contributes to a response that can outlast the individual molecules involved. This creates a problem when trying to turn the natural hormone into a medicine: a substance that is broken down so quickly cannot, by itself, provide a lasting effect from an occasional dose.

Semaglutide was designed around that limitation. It is a modified version of GLP-1 that can activate the same receptor while remaining in the body much longer, allowing the signaling pathway to be engaged under conditions very different from the brief rise and fall of the natural hormone after a meal. This is what the technical language is describing when semaglutide is called a GLP-1 analog and receptor agonist: it resembles the natural hormone closely enough to act through its receptor, but has been altered so that its effects can persist. The terminology matters less than the distinction underneath it. Semaglutide uses an existing biological signaling system while changing the duration and pattern of exposure to that signal. Semaglutide is the active drug itself; Ozempic is one of the brand names under which it is sold.

The modifications that make this possible work in two related ways: semaglutide is harder for the relevant enzyme to break down, and it can attach to a blood protein called albumin, which helps protect it and slows its removal by the kidneys. Together, those changes extend its persistence from minutes to days. The difference is often expressed as half-life, the time required for the amount of a substance to fall by half. For active natural GLP-1, that is roughly one to two minutes; for semaglutide, it is approximately a week. That does not mean the drug works for exactly seven days and then disappears. Its level declines gradually, just as a long half-life does not imply that a person experiences the same degree of fullness throughout that period. Drug concentration and the experience of hunger are connected through the physiology discussed here, but they remain different measurements.

The consequence is that semaglutide can continue influencing the system between meals, long after a particular meal has been digested, so its presence is much less closely tied to the arrival of food than the release of natural intestinal GLP-1. That persistence does not mean every effect is continuously amplified. Its influence on insulin release still depends on the glucose available, while effects on appetite and gastric function cannot be inferred simply from how long the drug remains in circulation. Semaglutide therefore does more than stretch an ordinary meal response across several days. By activating the same receptor through a very different pattern of exposure, it changes the conditions under which that signaling occurs. Weight loss becomes easier to understand from there, not as a separate property of the drug, but as one downstream consequence of what prolonged receptor activation can do to eating.

Weight loss enters the picture largely through what happens to eating. When energy intake remains below energy use over time, stored energy, including body fat, contributes more to meeting the difference. Semaglutide can help create those conditions by influencing appetite, satisfaction during and after meals, and the amount of food consumed. The loss of body fat is therefore downstream of changes in eating rather than evidence that the drug directly dissolves fat. This also clarifies why glucose regulation and weight loss belong to the same biological story without being the same process. Changes in insulin and glucagon help explain how glucose is handled after food arrives, while changes in intake help explain why less energy enters the system in the first place. Both can follow activation of the GLP-1 receptor, but they describe different consequences of that signaling and should remain conceptually separate.

Human experiments support reduced food intake as an important part of this explanation. In one small study, 30 adults with obesity but without diabetes received semaglutide and placebo during separate treatment periods and consumed about 24 percent less energy during laboratory meals and snacks while taking semaglutide. The researchers also measured resting metabolism and, after accounting for differences in lean body mass, did not find a statistically significant increase with the drug. Under those measured conditions, the result points toward reduced intake rather than a demonstrated increase in resting calorie expenditure. It does not exclude every other contribution to weight change, and the 24 percent reduction observed during laboratory meals should not be treated as a prediction of how much any individual will eat from day to day. What the experiment provides is narrower and more useful: evidence that semaglutide can alter energy intake substantially without requiring an increase in resting metabolism to explain the effect.

It would be equally misleading to attribute the whole effect to food staying in the stomach longer. In a 20-week study of 72 adults with obesity, semaglutide reduced intake at a laboratory lunch, but an indirect test did not detect delayed stomach emptying. Another, smaller study found a delay when researchers directly imaged the emptying of a solid meal. That study involved 20 women with obesity and polycystic ovary syndrome, a hormonal condition, so its results cannot simply be assumed to apply to older men. The studies used different measurements and involved different populations and treatment conditions. Their disagreement leaves questions open about when and how much stomach emptying contributes. It does not justify dismissing the stomach effect, or making it the entire explanation. Changes in eating can involve more than one pathway, and the research does not assign a precise share of weight loss to each one.

The experience of appetite can also change over time without food intake necessarily returning to its previous level. In a 60-week trial, people receiving semaglutide continued to eat less at a laboratory lunch than those receiving placebo even after several earlier differences in reported appetite were no longer statistically clear. The distinction is useful because subjective sensation and observed eating behavior are related without being interchangeable: a person does not necessarily need to experience an increasingly powerful or constant sense of fullness for intake to remain lower. The study included participants who did not complete later assessments, so the longer-term comparison carries some uncertainty, but the broader pattern across these experiments remains informative. Altered eating accounts for a substantial part of the explanation for weight loss, while the contribution and subjective experience of individual pathways can change over time. Receptor activation begins the physiological sequence; the eventual change in body weight emerges through what that signaling does to eating and, over time, energy balance.

Return to that ordinary lunch. As nutrients move through the digestive tract, pancreatic hormones, gastric function, nerve pathways, and signals involved in eating are changing together rather than operating as separate events. GLP-1 participates at several points in that response, which is why a drug acting through its receptor can influence both blood glucose and food intake without requiring one effect to explain the other. Encountered separately, those outcomes can seem almost unrelated: one belongs to the language of diabetes, the other to conversations about appetite and weight. Seen as parts of the same post-meal network, the connection becomes clearer. The useful insight is not that GLP-1 controls the entire response, but that altering one signaling pathway can influence several processes because that pathway is embedded within a system whose parts are already interacting.

Semaglutide builds on that biology by remaining available much longer than the natural hormone, activating the same receptor under conditions that extend well beyond the timing of an individual meal. The important change is therefore not simply the presence of a familiar signal, but its duration and pattern of exposure. From that difference can follow changes in glucose regulation, appetite, food intake, and eventually body weight, although the contribution and experience of those effects vary. Sharing a receptor does not make the natural hormone and the medicine interchangeable; it makes their differences more informative. Keeping GLP-1, its receptor, and semaglutide conceptually separate allows the biology to remain coherent as newer medicines build on the same signaling system in increasingly different ways.

It emerges from how multiple systems interact and adapt over time, often in ways that aren’t obvious when viewed in isolation.

If you want a clearer way to think about that, I’ve outlined the systems perspective in a short guide you can download here:

The Midlife Health Reset — 10 core systems that shape strength, energy, and long-term health after 50.

Sources

Müller, T. D., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130.

Beutler, L. R. (2026). GLP-1 physiology and pharmacology along the gut-brain axis. The Journal of Clinical Investigation, 136(2), e194744.

Kapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M. B., & Flint, A. (2017). Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: A randomised, double-blind, placebo-controlled trial. Diabetologia, 60(8), 1390–1399.

Blundell, J., et al. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 19(9), 1242–1251.

Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism, 23(3), 754–762.

Jensterle, M., et al. (2023). Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, Obesity and Metabolism, 25(4), 975–984. Abstract reviewed.

Tronieri, J. S., et al. (2026). Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: A 60-week, double-blind randomized controlled trial. The American Journal of Clinical Nutrition, 124(2), 101403.